Every material Form 8-K Instil Bio, Inc. has filed with the SEC since April 03, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Instil Bio reported a second-quarter 2026 net loss of $4.3 million, or $0.63 per share, down from $21.4 million, or $3.24 per share, a year earlier. The company had $69.9 million in cash and marketable securities at June 30, 2026, down from $76.3 million at December 31, 2025, and expects that balance to fund its operating plan beyond 2027. Shareholders are seeing a much smaller loss, but the company is also evaluating acquisitions and in-licensing deals that could change its spending.
Q2 2026 net loss was $4.3 million ($0.63 per share), versus $21.4 million ($3.24 per share) in Q2 2025.
In-process R&D expense was nil in Q2 2026, compared with $10.0 million in Q2 2025.
Cash, cash equivalents, restricted cash and marketable securities were $69.9 million at June 30, 2026, versus $76.3 million at December 31, 2025.
Instil is evaluating potential acquisitions, in-licensing and related opportunities.
Instil Bio reported a first quarter 2026 net loss of $4.2 million, or $0.62 per share, compared with a net loss of $28.2 million, or $4.32 per share, a year earlier. The company also said it is evaluating potential acquisitions and in-licensing deals, though it gave no assurance any transaction will occur.
Q1 2026 net loss was $4.2 million ($0.62 per share) versus $28.2 million ($4.32 per share) in Q1 2025.
Research and development expenses fell to $0.7 million from $5.4 million, and restructuring and impairment charges fell to $1.0 million from $16.1 million.
Cash, cash equivalents, restricted cash and marketable securities totaled $74.7 million at March 31, 2026, down from $76.3 million at December 31, 2025, and are expected to fund the current operating plan beyond 2027.
Instil Bio's Audit Committee dismissed Deloitte & Touche LLP as its independent accounting firm effective April 1, 2026, and appointed RSM US LLP for the fiscal year ending December 31, 2026. The filing states Deloitte's reports on the 2025 and 2024 financial statements contained no adverse opinion, disclaimer, or qualification, and that there were no disagreements or reportable events.
Audit Committee approved RSM US LLP as auditor on April 1, 2026 for fiscal year ending December 31, 2026
Deloitte & Touche LLP was dismissed effective April 1, 2026
Deloitte's reports for fiscal 2025 and 2024 had no adverse opinion, disclaimer, or qualification
Deloitte's letter to the SEC, dated April 3, 2026, is filed as Exhibit 16.1
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Instil Bio, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →